Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Seelos Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the agreement with Seelos Therapeutics, has acquired a worldwide license from iX Biopharma for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a technology known as Wa...
Product Name : Wafermine
Product Type : Controlled Substance
Upfront Cash : $9.0 million
November 24, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Seelos Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition